Coffee with Samso – Echo IQ Limited: AI Diagnostics, Mayo Clinic & the Path to a Cardiovascular Platform

A much awaited Coffee with Samso conversation with Dustin Haines from Echo IQ Limited (ASX: EIQ)is all about a clear investment narrative: this is not just an AI story, but a proven data-driven healthcare business building a scalable diagnostic platform anchored in real clinical need.

The main business for Echo IQ is in the cardiovascular diagnostics space, using artificial intelligence to analyse echocardiograms and assist physicians in identifying complex conditions such as aortic stenosis and heart failure. For those that are familiar in this space, this is where underdiagnosis remains a documented global issue. The business is built around clinical validation, regulatory pathways, and integration into hospital workflows, rather than purely theoretical AI capability.

The discussion in this epoisode of Coffee with Samso does highlight the realisation of the business model, which lays out the following:

• Clinical-grade AI with regulatory validation (FDA pathway)

• Access to a large, longitudinal echocardiography dataset (~2.2 million records)

• A clear commercial pathway into hospitals via existing diagnostic infrastructure

The Echo IQ story is no longer a "build it and hope" model. The recent news and what appears to be even more validation when the current FDA approval gets the tick, is that the business is now a measured progression from validation → approval → integration → revenue, which is what the market is valuing its future. This is often where many early-stage AI healthcare companies fall short.

In the words of Samso, get your favourite beverage and sit and listen to another great insight from Coffee with Samso.